Dengue in detail for CME, also provide probable cross question and answer . Also provide common patient question and answer in opd and er . And recent guidelines

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

dengue fever management guideline

Searching the Web

latest dengue clinical management guidelines 2025 2026 WHO

Reading File
Reading File
Reading File
Reading Web Page

https://communitymedicine4asses.wordpress.com/2025/07/11/who…

Searching Images

dengue fever petechial rash tourniquet test

Searching Images

WHO dengue classification warning signs severe dengue diagram

Searching Images

dengue skin rash exanthem

This clinical photograph displays a patient's abdomen and arm presenting a generalized, confluent erythematous rash, a characteristic cutaneous manifestation of Dengue Fever. The exanthem is marked by widespread, intense redness resulting from capillary dilatation and coalesced maculopapular lesions. A diagnostic hallmark visible here is the presence of 'islands of sparing'—small, rounded, or oval-shaped patches of normal-colored skin scattered throughout the erythematous background, often described as 'white islands in a sea of red'. These spared areas are randomly distributed across the affected trunk and limbs. The image serves as a key educational reference for recognizing the secondary rash phase of Dengue viral infection, typically occurring 3 to 6 days after the onset of fever. The visual presentation is essential for clinical diagnosis and differentiation from other viral exanthems, highlighting the specific immunologic response patterns seen in Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF).

This clinical photograph displays a patient's abdomen and arm presenting a generalized, confluent erythematous rash, a characteristic cutaneous manifestation of Dengue Fever. The exanthem is marked by widespread, intense redness resulting from capillary dilatation and coalesced maculopapular lesions. A diagnostic hallmark visible here is the presence of 'islands of sparing'—small, rounded, or oval-shaped patches of normal-colored skin scattered throughout the erythematous background, often described as 'white islands in a sea of red'. These spared areas are randomly distributed across the affected trunk and limbs. The image serves as a key educational reference for recognizing the secondary rash phase of Dengue viral infection, typically occurring 3 to 6 days after the onset of fever. The visual presentation is essential for clinical diagnosis and differentiation from other viral exanthems, highlighting the specific immunologic response patterns seen in Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF).

Clinical photography of a forearm demonstrates an acute, diffuse erythematous exanthem with pale islands of hypopigmentation or normal skin creating a white islands in a sea of red pattern. The imaging modality is surface, noninvasive dermatologic photography using standard lighting and color calibration; no stains or contrast agents applied. Anatomic context is the integumentary system, skin of the forearm (anterior-lateral aspect) in a febrile patient. Lesion morphology includes confluent erythema composed of macules and small papules merging to form broad red patches, with discrete islands of preserved or lighter skin within the inflamed background. The pattern may blanch with pressure and lacks overt vesiculation or necrosis in this view. Clinically this appearance is characteristic of viral exanthems seen in febrile illnesses such as dengue fever, chikungunya, or Zika; extension to trunk and limbs is common. Differential considerations include measles, rubella, drug eruption, pityriasis rosea, and pityriasis lichenoides. Diagnostic significance lies in recognizing a febrile exanthem pattern, prompting laboratory evaluation for dengue (NS1/IgM/IgG), complete blood count, and coagulation tests; monitor for warning signs. Potential educational uses include dermatology teaching, infectious disease triage, and documentation of rash evolution over time. This description supports rapid clinical triage and correlates with febrile dengue syndromes.

Clinical photography of a forearm demonstrates an acute, diffuse erythematous exanthem with pale islands of hypopigmentation or normal skin creating a white islands in a sea of red pattern. The imaging modality is surface, noninvasive dermatologic photography using standard lighting and color calibration; no stains or contrast agents applied. Anatomic context is the integumentary system, skin of the forearm (anterior-lateral aspect) in a febrile patient. Lesion morphology includes confluent erythema composed of macules and small papules merging to form broad red patches, with discrete islands of preserved or lighter skin within the inflamed background. The pattern may blanch with pressure and lacks overt vesiculation or necrosis in this view. Clinically this appearance is characteristic of viral exanthems seen in febrile illnesses such as dengue fever, chikungunya, or Zika; extension to trunk and limbs is common. Differential considerations include measles, rubella, drug eruption, pityriasis rosea, and pityriasis lichenoides. Diagnostic significance lies in recognizing a febrile exanthem pattern, prompting laboratory evaluation for dengue (NS1/IgM/IgG), complete blood count, and coagulation tests; monitor for warning signs. Potential educational uses include dermatology teaching, infectious disease triage, and documentation of rash evolution over time. This description supports rapid clinical triage and correlates with febrile dengue syndromes.

A clinical photograph showing a close-up of a patient's trunk and right axillary region on the third day of a rubelliform rash evolution. The image depicts a dense, generalized exanthem characterized by numerous small, erythematous maculopapular lesions. The morphology shows discrete reddish papules that are closely spaced, forming a nearly confluent, morbilliform-like pattern over the chest and abdomen. A distinctive clinical feature in this view is the relative sparing of the right axillary region, where the skin appears significantly less affected compared to the surrounding intensely red areas. The nipple and areola are visible and appear unaffected. The presentation is characteristic of an infectious viral exanthem, which in this clinical context was confirmed as a secondary dengue virus infection. The visual focus is on the morphology and distribution of the rash, providing an educational example of how systemic viral infections can manifest cutaneous signs while sparing certain anatomical regions.

A clinical photograph showing a close-up of a patient's trunk and right axillary region on the third day of a rubelliform rash evolution. The image depicts a dense, generalized exanthem characterized by numerous small, erythematous maculopapular lesions. The morphology shows discrete reddish papules that are closely spaced, forming a nearly confluent, morbilliform-like pattern over the chest and abdomen. A distinctive clinical feature in this view is the relative sparing of the right axillary region, where the skin appears significantly less affected compared to the surrounding intensely red areas. The nipple and areola are visible and appear unaffected. The presentation is characteristic of an infectious viral exanthem, which in this clinical context was confirmed as a secondary dengue virus infection. The visual focus is on the morphology and distribution of the rash, providing an educational example of how systemic viral infections can manifest cutaneous signs while sparing certain anatomical regions.

This clinical photograph displays a diffuse, erythematous maculopapular rash on the upper chest, neck, and shoulder of a patient. The dermatologic manifestation consists of numerous small, red macules (flat spots) and papules (slightly raised bumps) that are densely distributed across the skin surface. The pattern is characteristic of the exanthem seen in Zika virus infection, often described as a mild, dengue-like febrile illness. The image captures the anterior thoracic region near the clavicle and the lateral neck, illustrating the typical morphology and widespread distribution of the rash associated with flavivirus infections. This visual is a key educational resource for recognizing the clinical signs of emerging infectious diseases in a dermatology or emergency medicine context.

This clinical photograph displays a diffuse, erythematous maculopapular rash on the upper chest, neck, and shoulder of a patient. The dermatologic manifestation consists of numerous small, red macules (flat spots) and papules (slightly raised bumps) that are densely distributed across the skin surface. The pattern is characteristic of the exanthem seen in Zika virus infection, often described as a mild, dengue-like febrile illness. The image captures the anterior thoracic region near the clavicle and the lateral neck, illustrating the typical morphology and widespread distribution of the rash associated with flavivirus infections. This visual is a key educational resource for recognizing the clinical signs of emerging infectious diseases in a dermatology or emergency medicine context.

Clinical photograph of a patient's lower extremities demonstrating a widespread erythematous rash, characteristic of a viral exanthem. The left panel shows the thighs and knees, while the right panel shows the lower legs and dorsal feet. The morphology is primarily maculopapular, consisting of small, red, blanchable spots and slightly raised bumps. A distinct spatial variation is visible: the proximal lesions around the knees are highly confluent, forming large, poorly demarcated erythematous patches. In contrast, the distal lesions on the lower legs and feet are more discrete, individual maculopapules with intervening areas of normal-appearing skin. This presentation is consistent with the secondary stage of a Dengue virus infection (DENV-2), appearing several days after initial symptoms. The image serves as a clinical reference for identifying infectious disease-related skin manifestations and assessing the distribution and confluence of exanthematous eruptions.

Clinical photograph of a patient's lower extremities demonstrating a widespread erythematous rash, characteristic of a viral exanthem. The left panel shows the thighs and knees, while the right panel shows the lower legs and dorsal feet. The morphology is primarily maculopapular, consisting of small, red, blanchable spots and slightly raised bumps. A distinct spatial variation is visible: the proximal lesions around the knees are highly confluent, forming large, poorly demarcated erythematous patches. In contrast, the distal lesions on the lower legs and feet are more discrete, individual maculopapules with intervening areas of normal-appearing skin. This presentation is consistent with the secondary stage of a Dengue virus infection (DENV-2), appearing several days after initial symptoms. The image serves as a clinical reference for identifying infectious disease-related skin manifestations and assessing the distribution and confluence of exanthematous eruptions.

Searching Images

Aedes aegypti mosquito

A dual-panel graph illustrating the temporal trends of Gravid Ovillanta System (GOS) indices for Aedes mosquitoes, a critical entomological indicator in dengue vector surveillance. Panel A presents weekly data for an intervention group, while Panel B displays monthly data for a control group, spanning October 2018 to March 2020. Both panels feature a solid black line representing the total GOS Aedes index, complemented by a black dotted trend decomposition curve. Bar charts categorize the data into GOS aegypti (light grey) and GOS albopictus (dark grey) indices. In the intervention group (A), the mosquito population shows significant fluctuation with a prominent peak in abundance around June 2019 (weeks 24–26), followed by a gradual downward trend. In the control group (B), Ae. aegypti consistently demonstrates higher relative abundance compared to Ae. albopictus. This comparative data is used to evaluate the efficacy of trap deployment and community-based interventions in reducing mosquito density, which is a primary risk factor for the transmission of arboviral diseases like dengue.

A dual-panel graph illustrating the temporal trends of Gravid Ovillanta System (GOS) indices for Aedes mosquitoes, a critical entomological indicator in dengue vector surveillance. Panel A presents weekly data for an intervention group, while Panel B displays monthly data for a control group, spanning October 2018 to March 2020. Both panels feature a solid black line representing the total GOS Aedes index, complemented by a black dotted trend decomposition curve. Bar charts categorize the data into GOS aegypti (light grey) and GOS albopictus (dark grey) indices. In the intervention group (A), the mosquito population shows significant fluctuation with a prominent peak in abundance around June 2019 (weeks 24–26), followed by a gradual downward trend. In the control group (B), Ae. aegypti consistently demonstrates higher relative abundance compared to Ae. albopictus. This comparative data is used to evaluate the efficacy of trap deployment and community-based interventions in reducing mosquito density, which is a primary risk factor for the transmission of arboviral diseases like dengue.

A comparison chart consisting of three logarithmic dot plots illustrating the targeted sequencing coverage of Voltage-Gated Sodium Channel (VGSC) exons in three mosquito species: Aedes albopictus (n=24), Aedes aegypti (n=24), and Culex pipiens complex (n=8). The y-axis represents the sequencing depth per 0.1M read-pairs plus 1 on a logarithmic scale (1 to 1000), while the x-axis lists specific exons from 1 to 32. For each exon, two data points are provided: Median depth (MED, red) and Minimum depth (MIN, teal). The chart demonstrates that A. albopictus exhibits high and consistent coverage across all exons. In contrast, A. aegypti shows a significant drop in coverage for exons 2 and 16.5, and the C. pipiens complex displays variability with notable coverage dips in exons 2, 8, 14, 24, 29, and 32 (indicated by black dot markers). This visual data is critical for evaluating the efficiency of a single probe set designed for insecticide resistance research across different medically relevant mosquito vectors.

A comparison chart consisting of three logarithmic dot plots illustrating the targeted sequencing coverage of Voltage-Gated Sodium Channel (VGSC) exons in three mosquito species: Aedes albopictus (n=24), Aedes aegypti (n=24), and Culex pipiens complex (n=8). The y-axis represents the sequencing depth per 0.1M read-pairs plus 1 on a logarithmic scale (1 to 1000), while the x-axis lists specific exons from 1 to 32. For each exon, two data points are provided: Median depth (MED, red) and Minimum depth (MIN, teal). The chart demonstrates that A. albopictus exhibits high and consistent coverage across all exons. In contrast, A. aegypti shows a significant drop in coverage for exons 2 and 16.5, and the C. pipiens complex displays variability with notable coverage dips in exons 2, 8, 14, 24, 29, and 32 (indicated by black dot markers). This visual data is critical for evaluating the efficiency of a single probe set designed for insecticide resistance research across different medically relevant mosquito vectors.

This clinical photograph/specimen image displays late third-stage Aedes aegypti larvae within an experimental aquatic environment. The image is divided into two distinct horizontal layers: a superior dark, particulate-rich layer composed of powdered Azolla pinnata, and an inferior lighter, translucent water layer. Three larvae are visible, exhibiting an elongated, slender morphology with a whitish, translucent appearance. The specimens are positioned at the interface between the particulate material and the clear water, a behavior relevant to studying the larvicidal effects and toxic accumulation of botanical biocontrol agents. This visual demonstrates the behavioral responses and morphological status of mosquito larvae during a 24-hour bioassay test, serving as a reference for public health entomology and vector control research focusing on the reduction of human disease vectors like Aedes aegypti, which transmits dengue, zika, and chikungunya viruses.

This clinical photograph/specimen image displays late third-stage Aedes aegypti larvae within an experimental aquatic environment. The image is divided into two distinct horizontal layers: a superior dark, particulate-rich layer composed of powdered Azolla pinnata, and an inferior lighter, translucent water layer. Three larvae are visible, exhibiting an elongated, slender morphology with a whitish, translucent appearance. The specimens are positioned at the interface between the particulate material and the clear water, a behavior relevant to studying the larvicidal effects and toxic accumulation of botanical biocontrol agents. This visual demonstrates the behavioral responses and morphological status of mosquito larvae during a 24-hour bioassay test, serving as a reference for public health entomology and vector control research focusing on the reduction of human disease vectors like Aedes aegypti, which transmits dengue, zika, and chikungunya viruses.

Dengue Fever - CME Review

1. Overview & Virology

Dengue is caused by Dengue virus (DENV), a single-stranded RNA flavivirus with 4 serotypes (DENV-1 to DENV-4) transmitted by female Aedes aegypti and Aedes albopictus mosquitoes. Humans are the principal amplifying host. It is the most common arboviral infection worldwide and a leading cause of fever in returning travelers, endemic across Southeast Asia, the Western Pacific, the Americas, and parts of Africa - Rosen's Emergency Medicine.
Infection with one serotype gives lifelong immunity to that serotype but only transient cross-protection against others. Secondary infection with a different serotype is the key risk factor for severe disease via antibody-dependent enhancement (ADE) - non-neutralizing antibodies from the first infection form immune complexes that enhance viral uptake into monocytes/macrophages via Fc receptors, amplifying viral replication and triggering a cytokine storm - Robbins, Cotran & Kumar Pathologic Basis of Disease.
Incubation period: 4-10 days after the mosquito bite - Washington Manual of Medical Therapeutics.

2. Clinical Course - Three Phases (WHO framework)

A. Febrile phase (Days 1-3): Abrupt high-grade fever, severe frontal/retro-orbital headache, myalgia ("breakbone fever"), arthralgia, facial flushing, and a transient macular rash. Mild hemorrhagic manifestations (petechiae, positive tourniquet test, easy bruising) may appear. Leukopenia develops progressively.
B. Critical phase (around defervescence, typically Days 3-7): As temperature drops to ≤37.5-38°C, capillary permeability rises in parallel with a rising hematocrit. This is the window of plasma leakage, lasting 24-48 hours. Progressive leukopenia is followed by a rapid fall in platelet count, which usually precedes leakage. Pleural effusion (classically right-sided) and ascites may develop; gallbladder wall edema on ultrasound often precedes overt leakage. Patients without significant leakage improve; those with significant leakage may deteriorate into shock, marked by warning signs, and untreated can progress to organ hypoperfusion, metabolic acidosis, and DIC - Park's Textbook of Preventive and Social Medicine.
C. Convalescent/recovery phase (Days 7-10): Reabsorption of extravasated fluid, stabilizing hemodynamics, gradual rise in platelet and white cell counts. A confluent, itchy "islands of white in a sea of red" rash and bradycardia are classic at this stage.
Dengue exanthem showing islands of sparing

3. WHO 2009 Classification (still the operational framework)

CategoryCriteria
Dengue without warning signsFever + 2 of: nausea/vomiting, rash, aches/pains, leukopenia, positive tourniquet test
Dengue with warning signsAbdominal pain/tenderness, persistent vomiting, clinical fluid accumulation (effusion/ascites), mucosal bleeding, lethargy/restlessness, liver enlargement >2 cm, rising hematocrit with rapid platelet drop
Severe dengueSevere plasma leakage → shock (DSS) or fluid accumulation with respiratory distress; severe bleeding; severe organ impairment (AST/ALT ≥1000, altered consciousness/encephalitis, cardiac impairment/myocarditis)
  • Red Book 2021 (AAP); Andrews' Diseases of the Skin; Harrison's Principles of Internal Medicine 22E
Dengue Hemorrhagic Fever (DHF) requires all four: (1) increased vascular permeability, (2) thrombocytopenia, (3) fever 2-7 days, (4) hemorrhagic tendency. Dengue Shock Syndrome (DSS) = DHF plus circulatory shock - Rosen's Emergency Medicine.

4. Diagnosis

  • NS1 antigen: Positive from day 1, useful in the first 5 days of illness.
  • IgM ELISA: Detectable from day 4-5; may be falsely negative early.
  • RT-PCR / viral RNA: Most sensitive in the first 5 days (viremic phase).
  • IgG: Rises in secondary infection, useful epidemiologically.
  • Supportive labs: leukopenia, progressive thrombocytopenia, rising hematocrit (hemoconcentration), deranged LFTs, coagulopathy in severe disease.
  • Note: prior dengue vaccination can confound serologic interpretation - Red Book 2021.
Differential diagnosis: chikungunya, Zika, malaria, leptospirosis, rickettsial infections, measles, other viral hemorrhagic fevers (Ebola, Marburg, yellow fever) - Rosen's Emergency Medicine.

5. Management

No specific antiviral exists - treatment is entirely supportive.
  • Non-severe dengue (outpatient): Oral hydration, paracetamol for fever/pain. Strictly avoid NSAIDs and aspirin (bleeding risk, and aspirin carries Reye syndrome risk in children). Daily review for warning signs, especially around defervescence; monitor hematocrit/platelets.
  • Dengue with warning signs: Hospitalize. IV crystalloid rehydration titrated to urine output, vitals, and hematocrit trend; avoid fluid overload once leakage resolves (usually by 48 hours post-critical phase).
  • Severe dengue/DSS: ICU-level care, aggressive but carefully titrated IV fluid resuscitation, blood/platelet products only for significant bleeding (not for isolated thrombocytopenia), organ support as needed. Steroids are not recommended - evidence remains inconclusive/low quality - Rosen's Emergency Medicine, Washington Manual.

6. Recent Guidelines (2025 update)

The WHO released new Guidelines for the Clinical Management of Arboviral Diseases (dengue, chikungunya, Zika, yellow fever) in July 2025, using GRADE methodology - this supersedes prior WHO dengue guidance. Key new/reinforced recommendations:
  • Protocolized oral rehydration in non-severe dengue reduces hospital admissions with minimal harm.
  • Lactate measurement alongside standard monitoring is now recommended to guide IV fluid therapy in suspected/confirmed severe arboviral disease (strong recommendation) - likely reduces mortality (not useful in liver failure/yellow fever).
  • Passive leg raise (PLR) test suggested in shocked patients to judge fluid responsiveness before further boluses.
  • Systemic corticosteroids - recommended against use in severe arboviral disease (very low certainty evidence).
  • Paracetamol remains the antipyretic/analgesic of choice (avoid in yellow fever due to hepatic risk); metamizole/dipyrone suggested as an alternative where available.
  • Reaffirms avoidance of NSAIDs/aspirin throughout.
Additional 2025 developments:
  • Qdenga (TAK-003) is the WHO-endorsed dengue vaccine, recommended for children aged 6-16 years in high-transmission settings (2 doses, 3 months apart).
  • WHO Paediatric Drug Optimization (PADO) meeting (Oct 2025) is prioritizing pediatric-specific dengue therapeutics, reflecting the continued absence of a licensed antiviral.
Literature check: a 2025 systematic review (PMID 41037858) on dengue pathogenesis/diagnosis/management and a 2025 systematic review/meta-analysis on intracerebral hemorrhage in dengue (PMID 40776533) are current and consistent with the above - no conflicting recommendations identified.

Probable Cross-Questions & Answers (Viva/CME format)

Q1. Why does secondary infection with a different serotype increase risk of severe dengue? A: Antibody-dependent enhancement - pre-existing non-neutralizing heterotypic antibodies bind the new serotype and facilitate Fc-receptor-mediated uptake into monocytes/macrophages, increasing viral load and triggering an exaggerated cytokine response that drives plasma leakage.
Q2. What is the pathophysiological basis of shock in dengue, and how does it differ from septic shock? A: Dengue shock results from selective plasma leakage due to transient increased capillary permeability (not from myocardial depression or true vasodilatory sepsis), so it is typically responsive to timely, judicious crystalloid resuscitation and self-limited (24-48 hours), unlike septic shock's more protracted vasoplegia.
Q3. Why is hematocrit monitored rather than relying on platelet count alone to judge severity? A: Rising hematocrit reflects hemoconcentration from plasma leakage, which correlates with the degree of leakage and shock risk; platelet count falls in most dengue cases regardless of severity and does not itself predict bleeding or shock.
Q4. Why are NSAIDs and aspirin contraindicated? A: They inhibit platelet function and increase bleeding risk in a patient already thrombocytopenic and coagulopathic; aspirin additionally carries a theoretical Reye syndrome risk in children.
Q5. When would you consider transfusing platelets in a dengue patient? A: Only for significant active bleeding, not prophylactically for isolated thrombocytopenia without bleeding - prophylactic transfusion has not been shown to reduce bleeding risk or improve outcomes.
Q6. What imaging findings support diagnosis of plasma leakage before it's clinically obvious? A: Gallbladder wall edema on ultrasound often precedes overt leakage; chest X-ray (right pleural effusion) and abdominal ultrasound (ascites) can detect subclinical leakage.
Q7. How do you differentiate dengue with warning signs from severe dengue at the bedside? A: Warning signs (abdominal pain, persistent vomiting, mucosal bleeding, lethargy, hepatomegaly, rising Hct with falling platelets) indicate a patient needing hospitalization but who is not yet in shock/organ failure; severe dengue implies actual shock, severe bleeding, or severe organ impairment (AST/ALT ≥1000, encephalopathy, myocarditis) already present.
Q8. Why can early IgM serology be falsely negative? A: IgM typically doesn't rise until day 4-5 of illness; in the first few days, NS1 antigen or RT-PCR are more sensitive.
Q9. What is the role of steroids in severe dengue? A: Not recommended - available RCT/observational evidence is low quality and inconclusive; WHO's 2025 guideline explicitly recommends against systemic corticosteroids.
Q10. Why is a previously dengue-vaccinated or previously-infected patient at higher risk if infected again? A: Similar ADE mechanism - vaccine-induced or naturally-acquired antibodies against one serotype can enhance a subsequent infection with a different serotype, which is why Qdenga is restricted to high-transmission settings and specific age groups where net benefit outweighs this theoretical risk.

Common Patient Questions - OPD Setting

"I have fever and body ache, is it dengue? What test should I get?" If fever has been present for over 2-3 days, an NS1 antigen test (best in first 5 days) plus CBC (looking for falling platelets/leukopenia) is reasonable. IgM may still be negative early on. We will also check for warning signs at each visit.
"My platelet count is low, should I be scared?" A falling platelet count is expected in dengue and by itself is not dangerous. What we watch for is bleeding, or associated signs like abdominal pain, persistent vomiting, or a rapidly rising hematocrit - these matter more than the platelet number alone.
"Can I take a painkiller for my fever and body pain?" Only paracetamol (acetaminophen), at standard doses. Avoid ibuprofen, diclofenac, aspirin, or any NSAID - they increase bleeding risk in dengue.
"Do I need admission or can I manage this at home?" If you have no warning signs (no persistent vomiting, no abdominal pain, no bleeding, drinking fluids well), outpatient care with daily review is appropriate. We will re-check you daily, especially around day 4-6 when the fever drops - that's the highest-risk window.
"Is there a specific medicine or antiviral for dengue?" No. There is no antiviral treatment for dengue - management is entirely supportive (fluids, rest, paracetamol, monitoring).
"Can I get dengue again? Is there a vaccine?" Yes, you can get dengue up to four times (once per serotype), and a second infection can actually be more severe. A vaccine (Qdenga/TAK-003) exists and is recommended in some countries for children 6-16 years in high-transmission areas, but it isn't a routine vaccine for everyone and has specific eligibility criteria - discuss with your doctor.

Common Patient/Family Questions - ER Setting

"Why does the doctor keep saying the 'critical phase' when the fever has actually come down? Shouldn't they be getting better?" This is the counter-intuitive and most important teaching point: the drop in fever (defervescence, days 3-7) is exactly when the risk of shock is highest, not when the patient is safe. We monitor most closely at this time, not less closely.
"Why are you giving IV fluids if there's no dehydration from vomiting/diarrhea?" The fluid is leaking out of blood vessels into tissues (plasma leakage), not being lost through vomiting/stool. IV fluids replace what's leaking out of circulation and prevent shock; we carefully titrate the amount and stop once the leaking phase passes to avoid fluid overload.
"There's bleeding from the gums/nose - is this dangerous?" Mild mucosal bleeding (gums, nose, petechiae) is common and usually manageable; we're watching for whether it's significant/ongoing bleeding, which would need blood product support. This is one of the "warning signs" that determines whether admission is needed.
"Why isn't the doctor giving a platelet transfusion when the count is so low?" Platelet transfusion is reserved for active, significant bleeding - not given just because the number is low, since prophylactic transfusion doesn't prevent bleeding or improve outcomes in dengue and carries its own risks.
"My child/relative seems more tired and quiet than before - is that a bad sign?" Yes - lethargy or restlessness is a recognized warning sign of dengue and should be reported immediately; along with abdominal pain, persistent vomiting, and cold extremities, it can signal impending shock.
"How long until they are safe/can go home?" Once the critical phase passes (typically 24-48 hours after defervescence) without shock or bleeding, and platelet/hematocrit trends stabilize with the patient tolerating oral fluids, discharge can be considered - usually around day 7-10 of illness.
This is a shared conversation. Sign in to Orris to start your own chat.